Myriad Genetics First Quarter 2026 Financial Earnings

5/5/2026 | 1:30 pm PST / 4:30pm EST

Webcast Link
View Presentation

Events & Presentations

  • Myriad Genetics First Quarter 2026 Financial Earnings

    05/05/2026 | 1:30pm PDT / 4:30pm EDT

    Watch the webcast View the document

  • Barclays 28th Annual Global Healthcare Conference

    03/11/2026 | 9:00pm PDT / 12:00am EDT

  • Leerink Partners Global Healthcare Conference

    03/10/2026 | 10:40am PDT / 1:40pm EDT

    Watch the webcast
View all events

Financial Reports and Filings

Date Filing Title Downloads
06/23/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
06/23/2026 8-K Report of unscheduled material events or corporate event RTF XLS PDF HTML XBRL
06/12/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
06/12/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
06/09/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
06/08/2026 144 Filed by "insiders" prior intended sale of restricted stock. RTF XLS PDF HTML XBRL
06/05/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
06/05/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
06/05/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
06/05/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
View all filings

Latest News

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer Thumbnail

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer

Jul 02, 2026 | Products

Read more
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication Thumbnail

Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication

Jun 23, 2026 | Products

Read more
Myriad Genetics Names Raj Jampa as New Chief Technology Officer Thumbnail

Myriad Genetics Names Raj Jampa as New Chief Technology Officer

Jun 02, 2026 | Products

Read more
View all news releases

2025 Corporate Responsibility Report

Our Corporate Responsibility strategy reflects our vision for the future of healthcare. Building on more than 30 years of scientific leadership, we aim to invest with discipline and purpose. We are delivering insights that help people take control of their health and empower healthcare providers to better detect, treat, and prevent disease.

Read our 2025 Corporate Responsibility report to learn how we are working to advance innovation, strengthen our impact, and support the creation of long-term value for patients, providers, employees, and the communities we serve.

Read the report
2025 Corporate Responsibility Report

2025 Corporate Responsibility Report

Our Corporate Responsibility strategy reflects our vision for the future of healthcare. Building on more than 30 years of scientific leadership, we aim to invest with discipline and purpose. We are delivering insights that help people take control of their health and empower healthcare providers to better detect, treat, and prevent disease.

Read our 2025 Corporate Responsibility report to learn how we are working to advance innovation, strengthen our impact, and support the creation of long-term value for patients, providers, employees, and the communities we serve.

Read the report
2025 Corporate Responsibility Report